neurocoach.
My Care Plan
Explore optionsMedications

MEDICATIONS

Cannabis, CBD & cannabinoids

Defined medicines have specific approved uses. Anxiety, OCD and autism-related research remains limited or mixed; psychiatric risks matter.

NeuroCoach · Evidence explorerSources checked October 5, 2026Editorial draft · clinical review pending

How it works

Cannabis contains multiple active compounds. Purified prescription CBD, THC-containing products and retail oils are not interchangeable. A clinician discussion should identify the target symptom, formulation, evidence and individual risks.

What the evidence says, use by use

Evidence is specific to the condition, population and—for devices—the exact product. One label never covers everything.

Across conditions: Seizures associated with Lennox–Gastaut syndrome, Dravet syndrome or tuberous sclerosis complex

Established
Who was studied / who it’s for: Patients aged one year or older under specialist careRegulatory status: FDA approval is for prescription Epidiolex and these specific seizure indications.What this label means: Strong research and/or authoritative clinical guidelines support this specific use.

This approval does not establish effectiveness for autism, anxiety or OCD, or for other CBD products.

Sources: FDA

Anxiety: Anxiety symptom reduction

Emerging / limited
Who was studied / who it’s for: Small and varied research populationsWhat this label means: Early, small or mixed studies. Interesting, but not equivalent to established care.

Small studies show possible CBD signals; reliable routine benefit is not established. THC can worsen anxiety and paranoia.

Sources: NIH / NCCIH · CDC

OCD: OCD symptom reduction

Experimental
Who was studied / who it’s for: Adults in a small acute laboratory studyWhat this label means: Not established for routine use for this purpose. May be theoretical or in very early research.

A placebo-controlled study found no acute OCD symptom advantage from smoked THC- or CBD-dominant cannabis.

Sources: Kayser et al., Depression and Anxiety (2020)

Autism: Distressing co-occurring anxiety and related symptoms

Emerging / limited
Who was studied / who it’s for: Children in small trials; findings cannot be assumed for adultsWhat this label means: Early, small or mixed studies. Interesting, but not equivalent to established care.

A 2026 pilot missed its primary social-responsiveness endpoint; some secondary measures improved. Larger studies are needed.

Sources: Parrella et al., Autism Research (2026)

Who usually provides it

Discuss with the treating clinician, psychiatrist and pharmacist; legal medical-cannabis access is a separate assessment.

Cautions & things to know

  • Cannabis can provoke anxiety and paranoia and is associated with psychosis. A history of psychosis or schizophrenia requires particular caution and psychiatrist review.
  • CBD can interact with medicines and cause liver injury or sedation. Do not substitute a retail product for prescribed treatment.
  • Indica, sativa and terpene labels do not predict a safe or effective treatment for a particular condition.

Questions for a clinician

Conversation prompts, not a treatment plan.

  • What specific symptom and outcome would we monitor?
  • How does psychiatric history change the risks?
  • What are the interactions, monitoring requirements and established alternatives?

Educational, not medical advice. NeuroCoach is an educational and care-navigation resource, not a medical provider. Information about medications, supplements, therapies, devices, clinical trials and community experiences is provided for education and exploration and is not a recommendation, diagnosis or treatment plan. Evidence varies substantially among interventions. Decisions about medical or mental-health treatment should be made with an appropriately qualified healthcare professional. Do not start, stop or change medication, supplements or treatment based solely on information found here.

Sources

Sources checked October 5, 2026. Links support this page; they don’t imply endorsement of NeuroCoach.

  1. Epidiolex prescribing information (2025) FDA
  2. Cannabis and cannabinoids: what you need to know NIH / NCCIH
  3. Cannabis and mental health CDC
  4. Acute effects of cannabinoids on OCD: placebo-controlled laboratory study Kayser et al., Depression and Anxiety (2020)
  5. CBD and social relating, anxiety and parental stress: pilot crossover trial Parrella et al., Autism Research (2026)